After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
iBio Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of iBio Inc is $12.05M. A total of 1.54 million shares were traded on the day, compared to an average of 2.09M shares.
In the most recent transaction, Duran Felipe bought 9,191 shares of IBIO for 2.72 per share on Jan 10 ’25. After the transaction, the Chief Financial Officer now owns 11,139 company shares. In a previous transaction on Jan 10 ’25, Brenner Martin bought 9,191 shares at 2.72 per share. IBIO shares that the insider owns now total 18,316.
Among the insiders who bought shares, Banjak Marc acquired of 9,191 shares on Jan 10 ’25 at a per-share price of $2.72. This resulted in the Chief Legal Officer holding 11,066 shares of IBIO after the transaction. In another insider transaction, Arkowitz David bought 18,382 shares at $2.72 per share on Jan 10 ’25. Company shares held by the Director now total 18,382.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, IBIO has a high of $6.89 and a low of $0.56.
As of this writing, IBIO has an earnings estimate of -$0.29 per share for the current quarter. EPS was calculated based on a consensus of 2.0 estimates, with a high estimate of -$0.25 per share and a lower estimate of -$0.34. The company reported an EPS of -$0.74 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. IBIO’s latest balance sheet shows that the firm has $33.52M in Cash & Short Term Investments as of fiscal 2022. There were $25.77M in debt and $30.44M in liabilities at the time. Its Book Value Per Share was $1.13, while its Total Shareholder’s Equity was $63.48M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IBIO is Buy with a score of 4.33.
